[Catecholamine excretion and treatment of parkinsonism with midantan].
D000328:Adult; D000368:Aged; D000547:Amantadine / Q000009:adverse effects / Q000627:therapeutic use*; D002395:Catecholamines / Q000652:urine*; D004295:Dihydroxyphenylalanine / Q000652:urine; D004298:Dopamine / Q000652:urine; D004837:Epinephrine / Q000652:urine; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000652:urine; D010300:Parkinson Disease / Q000188:drug therapy* / Q000652:urine; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy; D010302:Parkinson Disease, Secondary / Q000188:drug therapy
D002395:Catecholamines; D004295:Dihydroxyphenylalanine; D000547:Amantadine; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine
Lechenie parkinsonizma midantanom i ékskretsiia katekholaminov